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We screened 23 children with severe respiratory syn-
cytial virus (RSV) disease and 23 children with mild RSV
disease for human metapneumovirus (HMPV). Although
HMPV was circulating in Connecticut, none of the 46 RSV-
infected patients tested positive for HMPV. In our study
population, HMPV did not contribute to the severity of RSV
disease. 
I
n the United States, 100,000 infants and young children
are hospitalized each year with respiratory syncytial
virus (RSV) bronchiolitis (1). Although the risk factors for
severe RSV disease, such as prematurity and bronchopul-
monary dysplasia, are well defined, severe RSV disease
may develop in otherwise healthy children. The pathogen-
esis of severe RSV disease is poorly defined. 
In 2001, van den Hoogen et al. reported the isolation of
a novel paramyxovirus, human metapneumovirus (HMPV)
from children with respiratory tract disease (2). HMPV has
been identified worldwide (3–7) and appears to have a sea-
sonal distribution (winter and spring) (8). Since the circu-
lation of HMPV may overlap with that of RSV,
simultaneous infection with both RSV and HMPV may
contribute to severe disease. Greensill et al. (9) reported
that 70% of RSV-infected children who required admis-
sion to the Pediatric Intensive Care Unit (PICU) in
Liverpool, U.K. were co-infected with HMPV. 
We sought to determine whether infection with HMPV
was associated with the severity of RSV disease. We deter-
mined the frequency of HMPV infection in children with
either mild or severe RSV disease. Disease severity was
assessed by both the disposition (PICU vs. non-PICU) and
by a clinical severity score. 
The Study 
As part of an ongoing epidemiologic study of viral res-
piratory infections in children, we collected all the RSV
direct fluorescent antibody (DFA)–positive respiratory
specimens from the Clinical Virology Laboratory at Yale-
New Haven Hospital from November 1, 2001, to October
31, 2002. All respiratory specimens were also screened by
DFA for parainfluenza viruses 1–3, influenza A and B
viruses, and adenoviruses (10). Any RSV-positive patient
who also tested positive for one of the viruses listed above
was excluded from the study. All RSV-positive children
admitted to PICU during this yearlong period were identi-
fied. Because the peak time of infection with RSV and
with HMPV may differ, each RSV-positive child from
PICU was matched by date of diagnosis with a child with
mild RSVdisease. All RSV-positive children who were not
admitted to PICU and diagnosed within 2 days of the diag-
nosis of the PICU-admitted child were identified. Of these,
the child whose age most closely matched the age of the
PICU-admitted child was selected. If no child diagnosed
with RSV was identified within 2 days of the PICU-admit-
ted child, the child with the closest date of diagnosis was
identified and matched to the PICU-admitted patient. 
RNA extraction and reverse transcription–polymerase
chain reaction (RT-PCR) were performed as previously
described (4). Primers used for the amplification of the
RSV L gene were as follows: forward primer 5′-GGTA-
GAATCTACATATCCTTACCTAAGTG-3′ (genome loca-
tion 14881–14909, [reference strain RSV A Melbourne,
Australia/2/’61] GenBank accession no. M74568), reverse
primer 5′-CGAGATATTAGTTTTTGACAC-3′ (genome
location 15190–15210, GenBank accession no. M74568).
The HMPV forward primer, 5′-GCGCGTTCTGAG-
GACAGGTTGG-3′ (HMPV genome location 3163-3180,
GenBank accession no. AF371367, G/C clamps are under-
lined) and reverse primer, 5′-GCGCTCAAGCCGGATG-
GTTTTGG-3′ (3425–3444, GenBank accession no.
AF371367, G/C clamps are underlined) used for the ampli-
fication of the HMPV F gene were based on regions of the
F gene conserved in New Haven, Netherlands, and
Australian strains (4). PCR reactions were performed by
using HotStar (Qiagen, Inc., Valencia, CA) and amplifica-
tion cycles were as follows: 95°C for 15 min followed by
35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for
1 min, and a final 10-min cycle at 72°C. Each set of reac-
tions contained appropriate negative (water) and positive
control samples for the RT (HMPV-positive nasal wash)
and the PCR (HMPV cDNA) steps. 
A clinical severity score (CSS) was adapted from the
severity score described by Martinello et al. (11). Two
points were assigned if the patient required positive-pres-
sure ventilatory support during the illness, and one point
was assigned for each of the following: hospital admission,
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USAhospitalization for >5 days, oxygen saturation <87% (at
least one measurement), and any use of supplemental oxy-
gen. Therefore, CSS ranged from 0 to 6. Medical records
from all patients were abstracted and scored by a reviewer
who did not know the patient’s HMPV status. 
On the basis of the published literature (9), we expect-
ed the frequency of RSV/HMPV co-infection in the PICU
patients to be approximately 70%, and in the non-PICU
patients to be closer to the DFA-negative–HMPV-positive
infection rate of 6.4% found in our population (DFA-neg-
ative refers to samples that tested negative for RSV, parain-
fluenza viruses, influenza viruses, and adenovirus) (4).
Power calculations were performed by using PASS 2002
(J. Hintze, NCSS and PASS, Number Cruncher Statistical
Systems, Kaysville, Utah). By using a power of 90% and
α of 0.05, a sample of 12 patients in each group would be
sufficient to support these findings (70% vs. 6.4%). By
using the same power calculations, 23 patients in each
group would provide adequate power to show as little as a
45% difference in proportions with co-infection between
the two groups. Comparisons were made by using the chi-
square test and Wilcoxon rank sum tests, as appropriate
(Table). Exact 95% confidence intervals were calculated in
SAS V8.2 (SAS Institute, Cary, NC). 
Twenty-three RSV DFA-positive patients were admit-
ted to PICU during the study period, and 23 matched
patients were identified. Demographic and clinical infor-
mation were obtained for each patient from the medical
record. Of the children admitted to PICU, 7 (30.4%) of 23
had a known predisposing risk factor for severe RSV dis-
ease. All the PICU-admitted children had CSS >3 and most
(16 [70.0%] of 23) had a CSS >5. Eighteen (78.2%) of 23
PICU patients were hospitalized for >5 days. None of the
RSV-positive patients admitted to the PICU tested positive
for HMPV by RT-PCR. 
Children with mild RSV disease were initially seen in
the emergency department, and according to their severity
of illness, either were discharged or were admitted to the
pediatric ward. Eight patients (34.8%) of the 23 mild RSV
disease group were admitted to the hospital, although only
4 (17.4%) of these children were hospitalized for >5 days.
The CSS range for this group was 0–4. Most patients (14
[61.0%] of 23) had a CSS of <3. None of these patients
were positive for HMPV by RT-PCR. 
Statistically significant differences between the PICU
group and the mild disease group were observed in admis-
sion age (median age 7 weeks vs. 54 weeks, p = 0.025),
hospital admission rate (23/23 vs. 8/23, p = 0.004) and
CSS (median CSS 5 vs. 1, p = 8 x 10–12) (Table). Positive
pressure ventilation was required by 17 (73.9%) of 23
PICU patients and 10 of these 17 patients needed it for >5
days. None of the patients screened in either group of
RSV-DFA positive patients had evidence of HMPV infec-
tion (p = 1.0). To ensure that the methods for RT-PCR were
adequate, we performed RT-PCR for RSV for each
patient’s respiratory specimen. Overall, 44 (95.7%) of 46
of children had a positive RT-PCR test for RSV. 
Conclusions
The possibility that HMPVplays a role in the pathogen-
esis of infections with other respiratory viruses is not
known. The importance of identifying HMPV in persons
with SARS remains to be explained (5,12). Greensill et al.
observed a 70% co-infection rate with HMPV and RSV
and a 90% co-infection rate among intubated infants with
HMPV and RSV admitted to their PICU (9). Although
Greensill et al. did not include an appropriate control
group in their study, these findings suggest that co-infec-
tion with both HMPV and RSV is common and that
together the two viruses may contribute to increase the
severity of disease. 
We did not observe HMPV infection in children with
either mild or severe RSV disease. Our findings cannot be
explained by the absence of HMPV in Connecticut. From
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Table. Comparison between the group of children admitted to PICU with severe RSV disease and the group of children with mild RSV 
disease 
Characteristic  PICU
a  Non PICU
a  Statistical comparison (p value) 
Median age (range)  7 wk (2 wk–21 mo)  54 wk (10 d–4 y)  0.025
b 
Prematurity (%)   5/23 (21.7)  3/23 (13.0)  > 0.1
c 
RSV
d PCR/DFA
e (%)   21/23 (91.3)  23/23 (100)  0.244
c 
Hospitalized (%)   23/23 (100)  8/23 (34.8)  0.004
c 
Median CSS
f (range)  5 (3–6)  1 (0–4)  < 0.001
b 
PPV
g (%)   17/23 (73.9)  0/23 (0)  ND
h 
RSV/HMPV
i co-infection   0/23 (0)  0/23 (0)  1.0 
aPICU, pediatric intensive care unit. 
bχ 2 test. 
cWilcoxon rank sum test. 
dRSV, respiratory syncytial virus. 
eDFA, direct fluorescent antibody screen. 
fCCS, clinical severity score. 
gPPV, positive pressure ventilation. 
hND, non-comparable because patients requiring PPV are admitted to the PICU.  
iHMPV, human metapneumovirus. November 2001 to April 2002 (the period of time when all
of the RSV-positive PICU-admitted children were identi-
fied), HMPV was detected in 11% of 446 patients who
tested negative by DFA for RSV, parainfluenza viruses,
influenza virus, and adenovirus (13) . Furthermore, we
matched children with mild RSV disease to children with
severe RSV disease by date of diagnosis to eliminate the
possibility that the temporal distribution of the viruses
might influence our results. 
The potential difference in the sensitivity of the screen-
ing tests used by Greensill et al. and our group likely does
not account for the differences in the observed rates of co-
infection. We used a similar RT-PCR–based approach. We
are confident that our methods to detect HMPV are both
sensitive and specific (4,13) . The observed rate of HMPV
in respiratory specimens in our previous study (8.1%) (13)
is comparable to rates observed elsewhere (6,14) .
Furthermore, in our previous studies, we have used
sequence analysis of RT-PCR amplicons to confirm the
identification of HMPV (4,13). An increased prevalence of
HMPV in Liverpool, UK, may account for the high rate of
RSV/HMPV co-infection observed by Greensill et al.,
although no data at this point support this hypothesis. 
Our relatively small sample size limited the power of
our analysis. However, on the basis of the sample size cal-
culations with 90% power, our patient numbers were suf-
ficient to detect a difference of >45% above the rate of
HMPV infection in the non-PICU group (6.4%).
Nonetheless, our results demonstrate that the rate of co-
infection is low (0% of 23 patients, 95% confidence inter-
val 0%–14.8%). Other studies also support our findings
that the frequency of co-infection with HMPV and RSV is
rare (7,14) 
The basis of the pathogenesis of severe RSV disease is
multifactorial. Since severe RSV disease may develop in
apparently healthy children, known host risk factors can-
not completely account for instances of severe illness.
Preexisting or maternally acquired immunity, innate
immunity, viral factors and genotypes and environment all
likely contribute to disease pathogenesis. Although we did
not detect co-infection, HMPV may worsen RSV disease
in a small percentage of infants. Nonetheless, HMPV most
likely does not play an important role in the severity of
RSV disease in the population. 
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